
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
The BioPharm International editors present our most popular video interviews from 2024.
The editors of BioPharm International® had the fortunate opportunity to sit down with several subject matter experts from the biopharmaceutical industry in 2024, with topics ranging from cell and gene therapies, messenger RNA, quality management, bispecific antibodies, and more.
The following are some of our most watched video interviews from 2024:
For more video interviews, visit BioPharmInternational.com. Check back throughout 2025 for the latest conference coverage. In addition, our Ask the Expert video series can be found at






